Trial Profile
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Vactosertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors MedPacto
- 17 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2020 Planned End Date changed from 1 Sep 2020 to 30 Dec 2022.
- 15 Jan 2020 Planned primary completion date changed from 25 Nov 2019 to 1 Oct 2022.